Pharmacologic methods to reduce perioperative bleeding

Transfusion

Volumn 48, Issue SUPPL. 1, 2008, Pages

  Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 8; CLOPIDOGREL; DESMOPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN GLUE; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; BLEEDING; BLOOD TRANSFUSION; BRAIN DISEASE; BRAIN TOXICITY; CARDIOPULMONARY BYPASS; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; ERYTHROCYTE TRANSFUSION; HEART FAILURE; HEART INFARCTION; HEART SURGERY; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MORTALITY; NEPHROTOXICITY; PERIOPERATIVE PERIOD; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; SURGICAL RISK; THROMBOEMBOLISM; VEIN THROMBOSIS;

6-AMINOCAPROIC ACID; APROTININ; DEAMINO ARGININE VASOPRESSIN; HEMORRHAGE; HEMOSTATICS; HUMANS; META-ANALYSIS AS TOPIC; ORTHOPEDICS; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; THORACIC SURGERY; TRANEXAMIC ACID;

EID: 43149119483     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01574.x     Document Type: Conference Paper

References (52)

1. Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001 72 : S1821 31.
2. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002 40 : 231 7.
3. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001 29 : 2271 5.
4. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 2005 112 (9 Suppl I276 80.
5. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001 72 : S1814 20.
6. Levy JH, Tanaka KA, Steiner ME. Evaluation and management of bleeding during cardiac surgery. Curr Hematol Rep 2005 4 : 368 72.
7. Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002 62 : 2193 211.
8. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004 351 : 683 94.
9. Mannucci PM. Hemostatic drugs. N Engl J Med 1998 339 : 245 53.
10. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001 345 : 588 95.
11. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997 90 : 2515 21.
12. Levi M, Cromheecke ME, de Jonge E, de Prins MH, de Mol B, Briet E, Buller HR. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999 354 : 1940 7.
13. Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery - a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost 1995 74 : 1064 70.
14. Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999 354 : 106 10.
15. Levy JH, Sypniewski E. Aprotinin: a pharmacologic overview. Orthopedics 2004 27 (6 Suppl s653 8.
16. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs 1999 57 : 233 60.
17. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000 355 : 1303 9.
18. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith PA. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995 92 : 2236 44.
19. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998 116 : 716 30.
20. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993 105 : 147 52.
21. Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H, Wolner E. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994 107 : 807 10.
22. Lemmer JH Jr, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, Schaff HV, Tatooles CJ, Rumberger JA. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994 107 : 543 51.
23. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004 128 : 442 8.
24. Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006 105 : 1034 46.
25. Shiga T, Wajima Z, Inoue T, Sakamoto A. Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials. Anesth Analg 2005 101 : 1602 7.
26. Miller BE, Tosone SR, Tam VK, Kanter KR, Guzzetta NA, Bailey JM, Levy JH. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998 66 : 535 40.
27. Smith PK, Datta SK, Muhlbaier LH, Samsa G, Nadel A, Lipscomb J. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. Ann Thorac Surg 2004 77 : 635 42.
28. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 65.
29. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007 297 : 471 9.
30. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006 46 : 327 38.
31. Levy JH, Despotis GJ, Spitznagel E. Should aprotinin continue to be used during cardiac surgery? Nat Clin Pract Cardiovasc Med 2006 3 : 360 1.
32. Levy JH. Aprotinin versus tranexamic acid: the controversy continues. Transfusion 2006 46 : 319 20.
33. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 17 : 2265 81.
34. Byar DP. Problems with using observational databases to compare treatments. Stat Med 1991 10 : 663 6.
35. Karkouti K, Djaiani G, Borger MA, Beattie WS, Fedorko L, Wijeysundera D, Ivanov J, Karski J. Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg 2005 80 : 1381 7.
36. Wijeysundera DN, Karkouti K, Beattie WS, Rao V, Ivanov J. Improving the identification of patients at risk of postoperative renal failure after cardiac surgery. Anesthesiology 2006 104 : 65 72.
37. Furnary AP, Wu Y, Hiratzka LF, Grunkemeier GL, Page US 3rd. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007 116 (11 Suppl I127 33.
38. Kincaid EH, Ashburn DA, Hoyle JR, Reichert MG, Hammon JW, Kon ND. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005 80 : 1388 93.
39. U.S. Food and Drug Administration. Aprotinin Injection (marketed as Trasylol) Information. Date created: February 8, 2006, updated November 5, 2007. Available from: http://www.fda.gov/cder/drug/infopage/aprotinin/default.htm
40. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999 57 : 1005 32.
41. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997 85 : 1258 67.
42. Wells PS. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. Am J Ther 2002 9 : 377 88.
43. Hiippala S, Strid L, Wennerstrand M, Arvela V, Mäntylä S, Ylinen J, Niemelä H. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth 1995 74 : 534 7.
44. Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemela HM, Mantyla SK, Kuisma RP, Ylinen JE. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 1997 84 : 839 44.
45. Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br 1996 78 : 434 40.
46. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, Roger SL, Glynn MF. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996 85 : 1043 8.
47. Kang Y, Lewis JH, Navalgund A, Russell MW, Bontempo FA, Niren LS, Starzl TE. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987 66 : 766 73.
48. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis. Circulation 1999 99 : 81 9.
49. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001 CD001886.
50. Steiner ME, Levy JH. Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol 2005 18 : 89 92.
51. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005 95 : 596 602.
52. Halkos ME, Levy JH, Chen E, Reddy VS, Lattouf OM, Guyton RA, Song HK. Early experience with activated recombinant factor VII for intractable hemorrhage after cardiovascular surgery. Ann Thorac Surg 2005 79 : 1303 6.